Vaccinia viruses: Vaccines against smallpox and vectors against infectious diseases and tumors

Expert Review of Vaccines

Volumn 10, Issue 8, 2011, Pages 1221-1240

  Walsh, Stephen R ^a   Dolin, Raphael ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

ACAM2000; clinical trials; Dryvax; IMVAMUNE; MVA; orthopoxviruses; smallpox; vaccine; vaccinia

Indexed keywords

ACAM 3000; CJ 50300; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

CANCER IMMUNIZATION; CELL CULTURE; CELLULAR IMMUNITY; HUMAN; MYOCARDITIS; NEUTROPENIA; NONHUMAN; PERICARDITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMALLPOX; SMALLPOX VIRUS; VACCINIA VIRUS;

ANIMALS; CANCER VACCINES; GENETIC VECTORS; HUMANS; NEOPLASMS; POXVIRIDAE INFECTIONS; SMALLPOX VACCINE; VACCINIA VIRUS;

EID: 80052057132     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.79     Document Type: Review

References (167)

1. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi I. Smallpox and its Eradication. World Health Organization, Geneva, Switzerland (1988)
2. Bray M, Buller M. Looking back at smallpox. Clin. Infect. Dis. 38(6), 882-889 (2004) (Pubitemid 38387240)
3. Henderson DA. Smallpox: clinical and epidemiologic features. Emerg. Infect. Dis. 5(4), 537-539 (1999) (Pubitemid 29418184)
4. Henderson DA, Inglesby TV, Bartlett JG, et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281(22), 2127-2137 (1999) (Pubitemid 29264692)
5. Moore ZS, Seward JF, Lane JM. Smallpox. Lancet 367(9508), 425-435 (2006) (Pubitemid 43184265)
6. Damon IK. Orthopoxviruses. In:Principles and Practice of Infectious Diseases, 7th Edition. Mandell GL, Bennett JE, Dolin R (Eds). Churchill Livingstone Elsevier, Philadelphia, PA, USA, 1923-1932 (2010)
7. WHO recommendations concerning the distribution, handling and synthesis of variola virus DNA, May 2008. Wkly Epidemiol. Rec. 83(44), 393-395 (2008)
8. Breman JG, Henderson DA. Diagnosis and management of smallpox. N. Engl. J. Med. 346(17), 1300-1308 (2002) (Pubitemid 34429463)
9. Jahrling PB, Fritz EA, Hensley LE. Countermeasures to the bioterrorist threat of smallpox. Curr. Mol. Med. 5(8), 817-826 (2005) (Pubitemid 43009520)
10. Bicknell WJ. The case for voluntary smallpox vaccination. N. Engl. J. Med. 346(17), 1323-1325 (2002) (Pubitemid 34436087)
11. Breman JG, Arita I, Fenner F. Preventing the return of smallpox. N. Engl. J. Med. 348(5), 463-466 (2003) (Pubitemid 36159367)
12. Bozzette SA, Boer R, Bhatnagar V, et al. A model for a smallpox vaccination policy. N. Engl. J. Med. 348(5), 416-425 (2003)
13. Meltzer MI, Damon I, LeDuc JW, Millar JD. Modeling potential responses to smallpox as a bioterrorist weapon. Emerg. Infect. Dis. 7(6), 959-969 (2001) (Pubitemid 33115774)
14. Weiss MM, Weiss PD, Mathisen G, Guze P. Rethinking smallpox. Clin. Infect. Dis. 39(11), 1668-1673 (2004) (Pubitemid 39578544)
15. Mack T. A Different view of smallpox and vaccination. N. Engl. J. Med. 348(5), 460-463 (2003)
16. Lane JM, Goldstein J. Evaluation of 21st Century risks of smallpox vaccination and policy options. Ann. Intern. Med. 138(6), 488-493 (2003) (Pubitemid 38129027)
17. LeDuc JW, Damon I, Relman DA, Huggins J, Jahrling PB. Smallpox research activities: U.S. interagency collaboration, 2001. Emerg. Infect. Dis. 8(7), 743-745 (2002) (Pubitemid 34764747)
18. Rosenthal SR, Merchlinsky M, Kleppinger C, Goldenthal KL. Developing new smallpox vaccines. Emerg. Infect. Dis. 7(6), 920-926 (2001) (Pubitemid 33115769)
19. Lane JM, Millar JD. Risks of smallpox vaccination complications in the United States. Am. J. Epidemiol. 93(4), 238-240 (1971)
20. Lane JM, Millar JD, Neff JM. Smallpox and smallpox vaccination policy. Annu. Rev. Med. 22, 251-272 (1971)
21. O'Connell CJ, Karzon DT, Barron AL, Plaut ME, Ali VM. Progressive vaccinia with normal antibodies. A case possibly due to deficient cellular immunity. Ann. Intern. Med. 60, 282-289 (1964)
22. Casey C, Vellozzi C, Mootrey GT, et al. Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR Recomm. Rep. 55(RR-1), 1-16 (2006)
23. Freed ER, Duma RJ, Escobar MR. Vaccinia necrosum and its relationship to impaired immunologic responsiveness. Am. J. Med. 52(3), 411-420 (1972)
24. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 316(11), 673-676 (1987) (Pubitemid 17032953)
25. Aragon TJ, Ulrich S, Fernyak S, Rutherford GW. Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963-1968. BMC Public Health 3, 26 (2003)
26. Casey CG, Iskander JK, Roper MH, et al. Adverse events associated with smallpox vaccination in the United States, January- October 2003. JAMA 294(21), 2734-2743 (2005) (Pubitemid 41770103)
27. Grabenstein JD, Winkenwerder W Jr. US military smallpox vaccination program experience. JAMA 289(24), 3278-3282 (2003) (Pubitemid 37430081)
28. Poland GA, Grabenstein JD, Neff JM. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 23(17-18), 2078-2081 (2005) (Pubitemid 40341430)
29. Update: adverse events following civilian smallpox vaccination - United States, 2003. MMWR Morb. Mortal. Wkly Rep. 53(5), 106-107 (2004)
30. Morgan J, Roper MH, Sperling L, et al. Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January-October 2003. Clin. Infect. Dis. 46(Suppl. 3), S242-S250 (2008) (Pubitemid 351590137)
31. Swerdlow DL, Roper MH, Morgan J, et al. Ischemic cardiac events during the Department of Health and Human Services Smallpox Vaccination Program, 2003. Clin. Infect. Dis. 46(Suppl. 3), S234-241 (2008) (Pubitemid 351590136)
32. Halsell JS, Riddle JR, Atwood JE, et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 289(24), 3283-3289 (2003) (Pubitemid 37430082)
33. Bray M, Wright ME. Progressive vaccinia. Clin. Infect. Dis. 36(6), 766-774 (2003) (Pubitemid 36337981)
34. Nell P, Kohl KS, Graham PL, et al. Progressive vaccinia as an adverse event following exposure to vaccinia virus: case definition and guidelines of data collection, analysis, and presentation of immunization safety data. Vaccine 25(31), 5735-5744 (2007) (Pubitemid 47049770)
35. Engler RJM, Kenner J, Leung DYM. Smallpox vaccination: risk considerations for patients with atopic dermatitis. J. Allergy Clin. Immunol. 110(3), 357-365 (2002)
36. Nell P, Kohl KS, Graham PL, et al. Eczema vaccinatum as an adverse event following exposure to vaccinia virus: case definition & guidelines of data collection, analysis, and presentation of immunization safety data. Vaccine 25(31), 5725-5734 (2007) (Pubitemid 47049767)
37. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part II. Adverse events. Clin. Infect. Dis. 37(2), 251-271 (2003) (Pubitemid 36930357)
38. Vellozzi C, Lane JM, Averhoff F, et al. Generalized vaccinia, progressive vaccinia, and eczema vaccinatum are rare following smallpox (vaccinia) vaccination: United States surveillance, 2003. Clin. Infect. Dis. 41(5), 689-697 (2005) (Pubitemid 41170359)
39. Talbot TR, Bredenberg HK, Smith M, LaFleur BJ, Boyd A, Edwards KM. Focal and generalized folliculitis following smallpox vaccination among vaccinia-naive recipients. JAMA 289(24), 3290-3294 (2003) (Pubitemid 37430083)
40. Walsh SR, Johnson RP. Vaccinia folliculitis after primary dryvax vaccination. Infect. Dis. Clin. Pract. 15(2), 132-134 (2007) (Pubitemid 46595019)
41. Kemper AR, Davis MM, Freed GL. Expected adverse events in a mass smallpox vaccination campaign. Eff. Clin. Pract. 5(2), 84-90 (2002)
42. Rotz LD, Dotson DA, Damon IK, Becher JA. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm. Rep. 50(RR-10), 1-25 (2001)
43. Wharton M, Strikas RA, Harpaz R, et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm. Rep. 52(RR-7), 1-16 (2003)
44. Slifka MK, Hanifin JM. Smallpox: the basics. Dermatol. Clin. 22(3), 263-274 (2004) (Pubitemid 38781723)
45. Cono J, Casey CG, Bell DM. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm. Rep. 52(RR-4), 1-28 (2003)
46. Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin. Investig. Drugs 17(4), 555-564 (2008) (Pubitemid 351578172)
47. Greenberg RN, Kennedy JS, Clanton DJ, et al. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet 365(9457), 398-409 (2005) (Pubitemid 40179226)
48. Weltzin R, Liu J, Pugachev KV, et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat. Med. 9(9), 1125-1130 (2003) (Pubitemid 37173695)
49. Jacobs BL, Langland JO, Kibler KV, et al. Vaccinia virus vaccines: past, present and future. Antiviral Res. 84(1), 1-13 (2009)
50. Cutchins E, Warren J, Jones WP. The antibody response to smallpox vaccination as measured by a tissue culture plaque method. J. Immunol. 85, 275-283 (1960)
51. McCarthy K, Downie AW, Bradley WH. The antibody response in man following infection with viruses of the pox group. II. Antibody response following vaccination. J. Hyg. (Lond.) 56(4), 466-478 (1958)
52. Belshe RB, Newman FK, Frey SE, et al. Dose-dependent neutralizing- antibody responses to vaccinia. J. Infect. Dis. 189(3), 493-497 (2004) (Pubitemid 38210586)
53. Couch RB, Winokur P, Edwards KM, et al. Reducing the dose of smallpox vaccine reduces vaccine-associated morbidity without reducing vaccination success rates or immune responses. J. Infect. Dis. 195(6), 826-832 (2007) (Pubitemid 46363927)
54. LeDuc JW, Becher J. Current status of smallpox vaccine. Emerg. Infect. Dis. 5(4), 593-594 (1999)
55. LeDuc JW, Jahrling PB. Strengthening national preparedness for smallpox: an update. Emerg. Infect. Dis. 7(1), 155-157 (2001)
56. Monath TP, Caldwell JR, Mundt W, et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) - a second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis. 8(Suppl. 2), S31-S44 (2004) (Pubitemid 39445966)
57. Marriott KA, Parkinson CV, Morefield SI, Davenport R, Nichols R, Monath TP. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine 26(4), 581-588 (2008)
58. Frey SE, Newman FK, Kennedy JS, et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine 27(10), 1637-1644 (2009)
59. Artenstein AW, Johnson C, Marbury TC, et al. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 23(25), 3301-3309 (2005) (Pubitemid 40523124)
60. Osborne JD, Da Silva M, Frace AM, et al. Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3. Vaccine 25(52), 8807-8832 (2007) (Pubitemid 350199592)
61. Beachkofsky TM, Carrizales SC, Bidinger JJ, Hrncir DE, Whittemore DE, Hivnor CM. Adverse events following smallpox vaccination with ACAM2000 in a military population. Arch. Dermatol. 146(6), 656-661 (2010)
62. Mack TM, Noble J Jr, Thomas DB. A prospective study of serum antibody and protection against smallpox. Am. J. Trop. Med. Hyg. 21(2), 214-218 (1972)
63. Sarkar J, Mitra A, Mukherjee M. The minimum protective level of antibodies in smallpox. Bull. World Health Organ. 52, 307-311 (1975)
64. Frey SE, Couch RB, Tacket CO, et al. Clinical responses to undiluted and diluted smallpox vaccine. N. Engl. J. Med. 346(17), 1265-1274 (2002) (Pubitemid 34429457)
65. McClain DJ, Harrison S, Yeager CL, et al. Immunologic responses to vaccinia vaccines administered by different parenteral routes. J. Infect. Dis. 175(4), 756-763 (1997) (Pubitemid 27142945)
66. Wiser I, Balicer RD, Cohen D. An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies. Vaccine 25(6), 976-984 (2007) (Pubitemid 44937441)
67. Jang HC, Kim CJ, Kim KH, et al. A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers. Vaccine 28(36), 5845-5849 (2010)
68. Kim SH, Choi SJ, Park WB, et al. Detailed kinetics of immune responses to a new cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 25(33), 6287-6291 (2007) (Pubitemid 47088029)
69. Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 24(47-48), 7009-7022 (2006) (Pubitemid 46107176)
70. Saito T, Fujii T, Kanatani Y, et al. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA 301(10), 1025-1033 (2009)
71. Meseda CA, Mayer AE, Kumar A, et al. Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model. Clin. Vaccine Immunol. 16(9), 1261-1271 (2009)
72. Wilck MB, Seaman MS, Baden LR, et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J. Infect. Dis. 201(9), 1361-1370 (2010)
73. Rivers TM. Cultivation of vaccine virus for Jennerian prophylaxis in man. J. Exp. Med. 54(4), 453-461 (1931)
74. Rivers TM, Ward SM. Jennerian prophylaxis by means of intradermal injections of culture vaccine virus. J. Exp. Med. 62(4), 549-560 (1935)
75. Kempe CH, Fulginiti V, Minamitani M, Shinefield H. Smallpox vaccination of eczema patients with a strain of attenuated live vaccinia (CVI-78). Pediatrics 42(6), 980-985 (1968)
76. Kempe CH. Smallpox vaccination of eczema patients with attenuated live vaccinia virus. Yale J. Biol. Med. 41, 1-12 (1968)
77. Jerome KR. Lennette's Laboratory Diagnosis of Viral Infections, 4th Edition. Informa Healthcare, New York, NY, USA (2010)
78. Speers WC, Wesley RB, Neff JM, Goldstein J, Lourie B. Evaluation of two kinds of smallpox vaccine: CVI-78 and calf lymph vaccine. II. Clinical and serologic observations of response to revaccination with calf lymph vaccine. Pediatr. Res. 9(8), 628-632 (1975)
79. Wesley RB, Speers WC, Neff JM, Ruben FL, Lourie B. Evaluation of two kinds of smallpox vaccine: CVI-78 and calf lymph vaccine. I. Clinical and serologic response to primary vaccination. Pediatr. Res. 9(8), 624-628 (1975)
80. Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244(2), 365-396 (1998) (Pubitemid 28384101)
81. Mayr A. Smallpox vaccination and bioterrorism with pox viruses. Comp. Immunol. Microbiol. Infect. Dis. 26(5-6), 423-430 (2003) (Pubitemid 37168477)
82. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72(5), 1031-1038 (1991)
83. Stittelaar KJ, Osterhaus ADME. MVA: a cuckoo in the vaccine nest? Vaccine 19(27), V-VI (2001) (Pubitemid 32522755)
84. Kennedy JS, Greenberg RN. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev. Vaccines 8(1), 13-24 (2009)
85. Frey SE, Newman FK, Kennedy JS, et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine 25(51), 8562-8573 (2007) (Pubitemid 350192042)
86. Parrino J, McCurdy LH, Larkin BD, et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax® challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 25(8), 1513-1525 (2007) (Pubitemid 46074296)
87. Vollmar J, Arndtz N, Eckl KM, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24(12), 2065-2070 (2006) (Pubitemid 43255148)
88. Seaman MS, Wilck MB, Baden LR, et al. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J. Infect. Dis. 201(9), 1353-1360 (2010)
89. von Krempelhuber A, Vollmar J, Pokorny R, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 28(5), 1209-1216 (2010)
90. Meisinger-Henschel C, Schmidt M, Lukassen S, et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J. Gen. Virol. 88(12), 3249-3259 (2007) (Pubitemid 350201834)
91. Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79(5), 1159-1167 (1998) (Pubitemid 28203857)
92. Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238(2), 198-211 (1997) (Pubitemid 28218138)
93. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl Acad. Sci. USA 89(22), 10847-10851 (1992)
94. Perkus ME, Tartaglia J, Paoletti E. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J. Leukoc. Biol. 58(1), 1-13 (1995)
95. Gomez CE, Najera JL, Krupa M, Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther. 8(2), 97-120 (2008)
96. Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev. Vaccines 7(7), 889-893 (2008)
97. Tykodi SS, Thompson JA. Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. Expert Opin. Biol. Ther. 8(12), 1947-1953 (2008)
98. Damon IK, Davidson WB, Hughes CM, et al. Evaluation of smallpox vaccines using variola neutralization. J. Gen. Virol. 90(Pt 8), 1962-1966 (2009)
99. Greenberg R, Von Krempelhuber A, Arndtz N, et al. The third generation smallpox vaccine IMVAMUNE®: update on the clinical immunogenicity. XVIII International Poxvirus, Asfivirus, and Iridovirus Symposium. Sedona, AZ. (2010)
100. Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc. Natl Acad. Sci. USA 79(23), 7415-7419 (1982) (Pubitemid 13179118)
101. Panicali D, Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Natl Acad. Sci. USA 79(16), 4927-4931 (1982)
102. Johnston JB, McFadden G. Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol. 6(8), 695-705 (2004) (Pubitemid 39077377)
103. Pastoret PP, Brochier B. The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur. Epidemiol. Infect. 116(3), 235-240 (1996) (Pubitemid 26191035)
104. Hanlon CA, Niezgoda M, Hamir AN, Schumacher C, Koprowski H, Rupprecht CE. First North American field release of a vaccinia-rabies glycoprotein recombinant virus. J. Wildl. Dis. 34(2), 228-239 (1998) (Pubitemid 128689322)
105. Slate D, Algeo TP, Nelson KM, et al. Oral rabies vaccination in North America: opportunities, complexities, and challenges. PLoS Negl. Trop. Dis. 3(12), e549 (2009)
106. Human vaccinia infection after contact with a raccoon rabies vaccine bait - Pennsylvania, 2009. MMWR Morb. Mortal. Wkly Rep. 58(43), 1204-1207 (2009)
107. Rupprecht CE, Blass L, Smith K, et al. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N. Engl. J. Med. 345(8), 582-586 (2001) (Pubitemid 32772100)
108. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(7), 1099-1105 (2010)
109. Hanke T, Goonetilleke N, McMichael AJ, Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J. Gen. Virol. 88(Pt 1), 1-12 (2007) (Pubitemid 46085108)
110. Mwau M, Cebere I, Sutton J, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85(Pt 4), 911-919 (2004) (Pubitemid 38489556)
111. Cebere I, Dorrell L, McShane H, et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1- uninfected volunteers. Vaccine 24(4), 417-425 (2006) (Pubitemid 41832544)
112. Guimaraes-Walker A, Mackie N, McCormack S, et al. Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine 26(51), 6671-6677 (2008)
113. Goonetilleke N, Moore S, Dally L, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)- specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J. Virol. 80(10), 4717-4728 (2006)
114. Dorrell L, Yang H, Ondondo B, et al. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J. Virol. 80(10), 4705-4716 (2006)
115. Goepfert PA, Elizaga M, Sato A, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J. Infect. Dis. 203(5), 610-619 (2011)
116. Ibanga HB, Brookes RH, Hill PC, et al. Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. Lancet Infect. Dis. 6(8), 522-528 (2006) (Pubitemid 44160476)
117. McShane H, Pathan AA, Sander CR, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10(11), 1240-1244 (2004) (Pubitemid 39540442)
118. Webster DP, Dunachie S, Vuola JM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl Sci. USA 102(13), 4836-4841 (2005) (Pubitemid 40471540)
119. Bejon P, Mwacharo J, Kai O, et al. A Phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin. Trials 1(6), e29 (2006)
120. Bejon P, Ogada E, Mwangi T, et al. Extended follow-up following a Phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS ONE 2(1), e707 (2007)
121. Amato RJ. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opin. Biol. Ther. 10(2), 281-287 (2010)
122. Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a Phase I trial. Lancet Oncol. 9(6), 533-542 (2008)
123. Zemp FJ, Corredor JC, Lun X, Muruve DA, Forsyth PA. Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. Cytokine Growth Factor Rev. 21(2-3), 103-117 (2010)
124. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004) (Pubitemid 39273730)
125. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu. Rev. Immunol. 24, 175-208 (2006)
126. Smith CL, Dunbar PR, Mirza F, et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int. J. Cancer 113(2), 259-266 (2005) (Pubitemid 39628316)
127. Dangoor A, Lorigan P, Keilholz U, et al. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol. Immunother. 59(6), 863-873 (2010)
128. Smith CL, Mirza F, Pasquetto V, et al. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J. Immunol. 175(12), 8431-8437 (2005) (Pubitemid 41798411)
129. Garber DA, O'Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS ONE 4(5), e5445 (2009)
130. Tartaglia J, Perkus ME, Taylor J, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188(1), 217-232 (1992)
131. Ockenhouse CF, Sun PF, Lanar DE, et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177(6), 1664-1673 (1998) (Pubitemid 28243593)
132. Bart PA, Goodall R, Barber T, et al. EV01: a Phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 26(25), 3153-3161 (2008)
133. Sheppard NC, Bates AC, Sattentau QJ. A functional human IgM response to HIV-1 Env after immunization with NYVAC HIV C. AIDS 21(4), 524-527 (2007)
134. McCormack S, Stohr W, Barber T, et al. EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 26(25), 3162-3174 (2008)
135. Harari A, Bart PA, Stohr W, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 205(1), 63-77 (2008) (Pubitemid 351185716)
136. Levy Y, Ellefsen K, Stöehr W, et al. Optimal priming of poxvirus vector (NYVAC)- based HIV vaccine regimens requires 3 DNA injections. Results of the randomized multicentre EV03/ANRS Vac20 Phase I/II Trial. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010
137. Asmuth DM, Brown EL, DiNubile MJ, et al. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J. Infect. Dis. 201(1), 132-141 (2010)
138. Esteban M. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum. Vaccin. 5(12), 867-871 (2009)
139. Nalca A, Zumbrun EE. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des. Devel. Ther. 4, 71-79 (2010)
140. Gomez CE, Najera JL, Jimenez EP, et al. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 25(15), 2863-2885 (2007) (Pubitemid 46412565)
141. Mooij P, Balla-Jhagjhoorsingh SS, Koopman G, et al. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J. Virol. 82(6), 2975-2988 (2008) (Pubitemid 351329186)
142. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209-2220 (2009)
143. Greenough TC, Cunningham CK, Muresan P, et al. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine 26(52), 6883-6893 (2008)
144. Harrer E, Bauerle M, Ferstl B, et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir. Ther. 10(2), 285-300 (2005) (Pubitemid 41151035)
145. Ramanathan VD, Kumar M, Mahalingam J, et al. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res. Hum. Retroviruses 25(11), 1107-1116 (2009)
146. Currier JR, Ngauy V, de Souza MS, et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara- HIV-1 vaccine candidate. PLoS ONE 5(11), e13983 (2010)
147. Amato RJ, Hawkins RE, Kaufman HL, et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled Phase III study. Clin. Cancer Res. 16(22), 5539-5547 (2010)
148. Harrop R, Shingler W, Kelleher M, de Belin J, Treasure P. Cross-trial analysis of immunologic and clinical data resulting from Phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. J. Immunother. 33(9), 999-1005 (2010)
149. Carvajal AA, de la Garza A, Cruz Quiroz BJ, et al. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a Phase I/II study. BioDrugs 21(1), 47-59 (2007) (Pubitemid 46232456)
150. Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther. 13(6), 592-597 (2006)
151. Berthoud TK, Hamill M, Lillie PJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin. Infect. Dis. 52(1), 1-7 (2011)
152. Arlen PM, Pazdur M, Skarupa L, Rauckhorst M, Gulley JL. A randomized Phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). Clin. Breast Cancer 7(2), 176-179 (2006) (Pubitemid 44044019)
153. CDC. Adverse reactions following smallpox vaccination. www.bt.cdc.gov/agent/smallpox/vaccination/pdf/reactions-vacc-clinic.pdf
154. Acambis. ACAM2000 Smallpox Vaccine. Vaccines and Related Biological Products Advisory Committee (VRBPAC) Briefing Document, Center for Biologics Evaluation & Research, Food and Drug Administration www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4292b2-02.pdf
155. Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers http://clinicaltrials.gov/ct2/show/NCT01056770
156. Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers http://clinicaltrials.gov/ct2/ show/NCT00103584
157. A Study to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naive Subjects http://clinicaltrials.gov/ct2/show/NCT01144637
158. Safety of and Immune Response to a Prime-boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults http://clinicaltrials.gov/ct2/show/ NCT00820846
159. A Study of MVA85A in Healthy Infants http://clinicaltrials.gov/ct2/show/ NCT00953927
160. A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV http://clinicaltrials.gov/ct2/show/NCT00731471
161. Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB http://clinicaltrials.gov/ct2/show/NCT00456183
162. Safety of and Immune Response to Prime/Boost Vaccine Regimens in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adults http://clinicaltrials.gov/ct2/show/ NCT00961883
163. Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers (EV03/ANRSVAC20) http://clinicaltrials.gov/ ct2/show/NCT00490074
164. Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults http://clinicaltrials.gov/ct2/show/NCT00301184
165. Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults http://clinicaltrials.gov/ct2/show/ NCT00574600
166. Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy http://clinicaltrials.gov/ct2/show/NCT01094405
167. Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer http://clinicaltrials.gov/ct2/show/NCT00179309